Leslie Walker

Some of America's top scholars on prescription drug pricing outline steps the Trump administration could take to make medicines more affordable.

Facing unprecedented pressure from the Trump administration, some of the world’s top drugmakers promise to cut prices. But experts say the savings might not be what they seem.

Every year, millions of people’s medical care runs into the roadblock known as prior authorization, which requires a patient’s health insurer to sign off before chemotherapy, surgery or countless other services can proceed. Who does this often onerous process help, who does it hurt and how could it work better for everyone?

Sweeping federal reforms force North Carolina and other states to make tough decisions about Medicaid coverage, costs and eligibility under mounting budget pressure.

North Carolina’s former health secretary explains the heavy lift and hard choices ahead of states as they rush to put Republicans' new health reforms in place.

As Republicans consider major changes to Medicaid and Obamacare, we asked a leading economist about the shockwaves these sharp policy shifts could send throughout the entire health care system.

Two new studies inject powerful evidence into the heated Medicaid debate in Washington, showing the public insurance program is saving lives.

We talk with Harvard researcher Ari Ne’eman about why the sharp policy shifts underway in Washington pose a unique threat to people with disabilities.

Medicare’s open enrollment season presents a challenging choice for its 67 million beneficiaries: selecting a new plan.

Some of the most powerful new medicines pose a host of challenges for drug companies trying to copy and sell similar versions on the cheap. Can those companies find a sustainable path forward, or will patients get left stuck paying exorbitant prices?